Clinical Immunotherapeutics

, Volume 5, Issue 2, pp 122–136 | Cite as

Topical Corticosteroid Therapy of Rhinitis

A Review
  • Niels Mygind
  • Valerie Lund
Review Article Drug Class Overview

Summary

The introduction of nasal corticosteroids 20 years ago has been the most important therapeutic progress in rhinitis management since the introduction of the first generation of antihistamines. Our knowledge of the mode of action of corticosteroids is still incomplete, although a series of intranasal studies has now clarified this problem as the airway mucous membrane of the nose is easily accessible for investigation. Nasal corticosteroids are a highly effective therapeutic modality that can be used for long term therapy of allergic rhinitis, perennial nonallergic rhinitis and nasal polyposis. Experience for 20 years has shown that the adverse effects from this type of treatment are negligible, and far less serious than those occurring in the skin following long term use of corticosteroid ointment. Intranasal corticosteroids can therefore be considered as first-line treatment for allergic and nonallergic rhinitis.

The major disadvantage of this type of treatment is the slow onset of action and the lack of effect on itchy eyes. For that reason, the second generation antihistamines are the drugs of choice in patients having occasional symptoms. However, in our opinion, intranasal corticosteroids are preferable in patients who have symptoms on a regular basis, either in the pollen season or all year.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pepys J, Hutchroft BJ. Bronchial provocation tests in etiologic diagnosis and analysis of asthma. Am Rev Respir Dis 1975; 112: 928–59Google Scholar
  2. 2.
    Bisgaard H, Gronborg H, Mygind N, et al. Allergen-induced increase of eosinophil cationic protein in nasal lavage fluid: effect of the glucocorticoid budesonide. J Allergy Clin Immunol 1990; 85: 891–5PubMedCrossRefGoogle Scholar
  3. 3.
    Horak F, Matthew H. The protective action of fluocortin butylester (FCB) in the nasal antigen provocation test: a controlled double-blind crossover study. Ann Allergy 1982; 48: 305PubMedGoogle Scholar
  4. 4.
    Okuda M, Senba O. Effect of beclomethasone dipropionate nasal spray on subjective and objective findings in perennial rhinitis. Clin Otolaryngol 1980; 53: 15–21Google Scholar
  5. 5.
    Pipkom U. Budesonide and nasal allergen challenge testing in man. Allergy 1982; 37: 129–34CrossRefGoogle Scholar
  6. 6.
    Pipkorn U, Proud D, Schleimer RP, et al. Effects of short term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J Clin Invest 1987; 80: 957–61PubMedCrossRefGoogle Scholar
  7. 7.
    Vilsviik JS, Jenssen AO, Walstad R. The effect of beclomethasone dipropionate aerosol on allergen induced nasal stenosis. Clin Allergy 1975; 5: 291–4CrossRefGoogle Scholar
  8. 8.
    Dahl R, Johansson S-Å. Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction. Eur J Respir Dis 1982; 63Suppl. 122: 167–75Google Scholar
  9. 9.
    Pipkorn U. Budesonide and nasal histamine challenge. Allergy 1982; 37: 359–63PubMedCrossRefGoogle Scholar
  10. 10.
    Pipkorn U. Effect of topical glucocorticoid treatment on nasal mucosal mast cells in allergic rhinitis. Allergy 1983; 38: 125–9PubMedCrossRefGoogle Scholar
  11. 11.
    Pipkorn U, Andersson P. Budesonide and nasal mucosal histamine content and anti-IgE induced histamine release. Allergy 1982; 37: 591–5PubMedCrossRefGoogle Scholar
  12. 12.
    Lindqvist N, Karlsson G, Pipkorn U. Adrenoceptor responsiveness of the allergic nasal mucosa. Effect of topical glucocorticoid treatment. ORL J Otorhinolaryngol Relat Spec. In pressGoogle Scholar
  13. 13.
    Bende M, Lindqvist N, Pipkorn U. The effect of a topical steroid, budesonide, on nasal mucosal blood flow as measured with 133Xe wash-out technique. Allergy 1983; 38: 461–4PubMedCrossRefGoogle Scholar
  14. 14.
    Baumgarten CR, Togias A, Naclerio RM, et al. Kininogens are generated following nasal challenge with allergen in allergen individuals but not in non-allergic individuals. J Clin Invest 1985; 76: 191–7PubMedCrossRefGoogle Scholar
  15. 15.
    Proud D, Togias A, Naclerio RM, et al. Kinins are generated in-vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest 1983; 72: 1678–85PubMedCrossRefGoogle Scholar
  16. 16.
    Pipkorn U, Proud D, Lichtenstein LM, et al. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 1987; 316: 1506–10PubMedCrossRefGoogle Scholar
  17. 17.
    Sørensen H, Mygind N, Pedersen CB, et al. Long term treatment of nasal polyps with beclomethasone dipropionate aerosol III. Acta Otolaryngol (Stockh) 1976; 82: 260–2CrossRefGoogle Scholar
  18. 18.
    Svensson C, Klementsson H, Andersson M, et al. Glucocorticoid-induced attenuation of mucosal exudation of fibrinogen and bradykinins in seasonal allergic rhinitis. Allergy 1994; 49: 177–83PubMedCrossRefGoogle Scholar
  19. 19.
    Grønborg H, Bisgaard H, Rømeling F, et al. Nasal symptom response to allergen provocation: effect of the glucocorticoid budesonide. Allergy 1993; 48: 87–93PubMedCrossRefGoogle Scholar
  20. 20.
    Bascom R, Wachs M, Naclerio RM, et al. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988; 81: 580–9PubMedCrossRefGoogle Scholar
  21. 21.
    Naclerio RM. Inflammation in allergic rhinitis. Res Clin Forums 1992; 14(3): 49–55Google Scholar
  22. 22.
    Okuda M, Othsuka H, Sakaguchi K, et al. Effect of anti-allergic treatment on nasal surface basophilic metachromatic cells in allergic rhinitis. Allergy Proc 1989; 10: 23–6PubMedCrossRefGoogle Scholar
  23. 23.
    Bascom R, Pipkorn U, Lichtenstein LM, et al. The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic corticosteroids. Am Rev Respir Dis 1988; 138: 406–12PubMedGoogle Scholar
  24. 24.
    Andersson M, Andersson P, Venge P, et al. Eosinophils and eosinophil cationic protein (ECP) in nasal lavages during allergen-induced hyperresponsiveness. Effect of topical glucocorticosteroid treatment. Allergy 1989; 44: 342–8PubMedCrossRefGoogle Scholar
  25. 25.
    Gomez E, Clague J, Gatland D, et al. Effect of topical corticosteroids on seasonally induced increase in nasal mast cells. BMJ 1988; 246: 1572–3CrossRefGoogle Scholar
  26. 26.
    Otsuka H, Denburg JA, Befus AD, et al. Effect of beclomethasone dipropionate on nasal metachromatic cell sub-population. Clin Allergy 1986; 16: 589–95PubMedCrossRefGoogle Scholar
  27. 27.
    Pipkorn U, Enerbäck L. Nasal mucosal mast cells and histamine in hay fever: effect of topical glucocorticoid treatment. Int Arch Allergy Appl Immunol 1987; 84: 123–8PubMedCrossRefGoogle Scholar
  28. 28.
    Meltzer EO, Orgel HA, Bronshy EA, et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. J Allergy Clin Immunol 1990; 86: 221–30PubMedCrossRefGoogle Scholar
  29. 29.
    Meltzer EO, Orgel HA, Rogenes PR, et al. Nasal cytology in patients with allergic rhinitis: effects of intranasal fluticasone propionate. J Allergy Clin Immunol 1994; 94: 708–15PubMedCrossRefGoogle Scholar
  30. 30.
    Mygind N, Sørensen H, Pedersen CB. The nasal mucosa during long-term treatment with beclomethasone dipropionate aerosol. A light and scanning electron microscopic study of nasal polyps. Acta Otolaryngol (Stockh) 1978; 85: 437–43Google Scholar
  31. 31.
    Andersson M, Andersson P, Pipkom U. Allergen-induced specific and non-specific nasal hyperreactivity. Reciprocal relationship and inhibition by topical glucocorticosteroids. Acta Otolaryngol (Stockh) 1989: 107; 270–7CrossRefGoogle Scholar
  32. 32.
    Andersson M, Andersson P, Pipkom U. Topical glucocorticosteroids and allergen-induced increase in nasal reactivity. Relationship between treatment time and inhibitory effect. J Allergy Clin Immunol 1988; 82: 1019–26PubMedCrossRefGoogle Scholar
  33. 33.
    Baroody F, Lichtenstein LM, Kagey-Sobotka A, et al. Topical steroids inhibit antigen-induced nasal hyperreactivity to histamine [abstract]. J Allergy Clin Immunol 1989; 82: 163Google Scholar
  34. 34.
    Ryan G, Latimer KM, Juniper EF, et al. Effect of beclomethasone dipropionate on bronchial responsiveness to histamine in controlled nonsteroid-dependent asthma. J Allergy Clin Immunol 1985; 75: 25–30PubMedCrossRefGoogle Scholar
  35. 35.
    Klementsson H, Svensson C, Andersson M, et al. Eosinophils, secretory responsiveness and glucocorticoid-induced effects on the nasal mucosa during a weak pollen season. Clin Exp Allergy 1991; 21: 705–10PubMedCrossRefGoogle Scholar
  36. 36.
    Malm L, Wihl J-Å, Lamm CJ, et al. Reduction of methacholine induced nasal secretions by the treatment with a new topical steroid in perennial non-allergic rhinitis. Allergy 1982; 36: 209–14CrossRefGoogle Scholar
  37. 37.
    Toft A, Wihl J-Å, Toxman J, et al. Double-blind comparison between beclomethasone dipropionate as aerosol and as powder in patients with nasal polyposis. Clin Allergy 1982; 12: 391–401PubMedCrossRefGoogle Scholar
  38. 38.
    van Wijk RG. Nasal hyperresponsiveness to histamine, methacholine and phentolamine in allergic rhinitis patients and controls. Clin Allergy 1987; 17: 563–70CrossRefGoogle Scholar
  39. 39.
    Holm AF, Fokkens WJ, Godthelp T, et al. Effect of 3 months’ nasal steroid therapy on nasal T cells and Langerhans cells in patients suffering from allergic rhinitis. Allergy 1995; 50: 204–9PubMedCrossRefGoogle Scholar
  40. 40.
    Kay AB. Asthma and inflammation. J Allergy Clin Immunol 1991; 87: 893–910PubMedCrossRefGoogle Scholar
  41. 41.
    Rak S, Jacobson MR, Sudderick RM, et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994; 24: 930–9PubMedCrossRefGoogle Scholar
  42. 42.
    Masuyama K, Rak S, Jacobson MR, et al. Rhinitis at the cellular level. Eur Respir Rev 1994; 4: 252–5Google Scholar
  43. 43.
    Kanai N, Denburg JA, Evans S, et al. Nasal polyp inflammation. Effect of topical nasal steroid. Am J Respir Crit Care Med 1994; 150: 1094–1100PubMedGoogle Scholar
  44. 44.
    Cox G, Ohtoshi T, Vancheri C, et al. Promotion of eosinophil survival by human bronchial epithelial cells and its modulation by steroids. Am J Respir Cell Mol Biol 1991; 4: 525–31PubMedGoogle Scholar
  45. 45.
    Mattoli S, Vittori E, Marini M. Corticosteroids downregulate the increased expression of GM-CSF, IL6 and IL8 in bronchial epithelium of asthmatic patients [abstract]. J Allergy Clin Immunol 1992; 89: 164Google Scholar
  46. 46.
    Brogden RN, Heel RC, Speight TM, et al. Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. Drugs 1984; 28: 99–126PubMedCrossRefGoogle Scholar
  47. 47.
    Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44(3): 375–407PubMedCrossRefGoogle Scholar
  48. 48.
    Naclerio RM, Mygind N. Intranasal steroids. In: Mygind N, Naclerio RM, editors. Allergic and non-allergic rhinitis: clinical aspects. Copenhagen: Munksgaard, 1993: 114–22Google Scholar
  49. 49.
    Pakes GE, Brogden RN, Heel RD, et al. Flunisolide: a review of its pharmacological properties and therapeutic efficacy in rhinitis. Drugs 1980; 19: 397–411PubMedCrossRefGoogle Scholar
  50. 50.
    Bryson HM, Faulds D. Intranasal fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Drugs 1992; 43(5) 760–75PubMedCrossRefGoogle Scholar
  51. 51.
    Siegel SC. Topical intranasal corticosteroid therapy in rhinitis. J Allergy Clin Immunol 1988; 81: 984–91PubMedCrossRefGoogle Scholar
  52. 52.
    Lund VJ. International consensus report on the diagnosis and management of rhinitis. Allergy 1994; 49Suppl. 19: 1–34Google Scholar
  53. 53.
    Norman PS, Winkenwerder WL, Agbayani BF, et al. Adrenal function during the use of dexamethasone aerosols in the treatment of ragweed hay fever. J Allergy Clin Immunol 1967; 40: 57–61Google Scholar
  54. 54.
    Stevens DJ. Cushing’s syndrome due to abuse of betamethasone nasal drops. J Laryngol Otol 1988; 102: 219–21PubMedCrossRefGoogle Scholar
  55. 55.
    Czarny D, Brostoff J. Effect of intranasal betamethasone-17-valerate on perennial rhinitis and adrenal function. Lancet 1968; 2: 188–90PubMedCrossRefGoogle Scholar
  56. 56.
    Mygind N. Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. BMJ 1973; 4: 464–6PubMedCrossRefGoogle Scholar
  57. 57.
    Turkeltaub PC, Norman PS, Crepea S. Treatment of ragweed hay fever with an intranasal spray containing flunisolide: a new synthetic corticosteroid. J Allergy Clin Immunol 1976; 58: 597–606PubMedCrossRefGoogle Scholar
  58. 58.
    Balle VH, Pedersen U, Engby B. Allergic perennial and non-allergic vasomotor rhinitis treated with budesonide nasal spray. Rhinology 1980; 18: 135–42PubMedGoogle Scholar
  59. 59.
    Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990; 84Suppl. A: 25–9PubMedCrossRefGoogle Scholar
  60. 60.
    Scadding GK, Lund VJ, Holmstrand M, et al. Clinical and physiological effects of fluticasone propionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinology 1991; Suppl. 11: 37–43Google Scholar
  61. 61.
    Dolovich J, Wong AG, Chodirker WB, et al. Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. Ann Allergy 1994; 72: 147–53Google Scholar
  62. 62.
    Findley S, Huber F, Garcia J, et al. Efficacy of once-a-day intranasal administration of triamcinolone acetonide in patients with seasonal allergic rhinitis. Ann Allergy 1992; 68: 228–32Google Scholar
  63. 63.
    Orgel HA, Meltzer EO, Bierman CW, et al. Intranasal fluocortin butyl in patients with perennial rhinitis: a 12-month efficacy and safety study including nasal biopsy. J Allergy Clin Immunol 1991; 88: 257–64PubMedCrossRefGoogle Scholar
  64. 64.
    Sahay JN, Chatterjee SS, Engler C. A comparative trial of flunisolide and beclomethasone dipropionate in the treatment of perennial allergic rhinitis. Clin Allergy 1980; 10: 65–70PubMedCrossRefGoogle Scholar
  65. 65.
    Welsh PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987; 62: 125–34PubMedCrossRefGoogle Scholar
  66. 66.
    Radner PH, Pauli BR, Findlay SR, et al. Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as beclomethasone dipropionate given twice daily. J Allergy Clin Immunol 1992; 90: 285–91CrossRefGoogle Scholar
  67. 67.
    van As A, Bronsky EA, Dockhorn RJ, et al. Once daily fluticasone propionate is as effective in perennial rhinitis as twice daily beclomethasone dipropionate. J Allergy Clin Immunol 1993; 91: 1146–54PubMedCrossRefGoogle Scholar
  68. 68.
    LaForce CF, Dockhorn RJ, Findlay SR, et al. Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. J Fam Pract 1994; 38: 145–52PubMedGoogle Scholar
  69. 69.
    Haye R, Gomez EG. A multicenter study to assess long-term use of fluticasone propionate aqueous nasal spray in comparison with beclomethasone dipropionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinology 1993; 31: 169–74PubMedGoogle Scholar
  70. 70.
    al Mohaimeid H. A parallel-group comparison of budesonide and beclomethasone dipropionate for the treatment of perennial allergic rhinitis in adults. J Int Med Res 1993; 21: 67–73PubMedGoogle Scholar
  71. 71.
    Vanzieleghem MA, Juniper EF. A comparison of budesonide and beclomethasone dipropionate nasal aerosols in ragweed-induced rhinitis. J Allergy Clin Immunol 1987; 79: 887–92PubMedCrossRefGoogle Scholar
  72. 72.
    McArthur JG. A comparison of budesonide and beclomethasone dipropionate sprays in the treatment of seasonal allergic rhinitis. Clin Otolaryngol 1994; 19: 537–42PubMedCrossRefGoogle Scholar
  73. 73.
    Storms W, Bronsky E, Findley S, et al. Once daily triamcinolone acetonide nasal spray is effective for the treatment of perennial allergic rhinitis. Ann Allergy 1991; 66: 329–34PubMedGoogle Scholar
  74. 74.
    Welch MJ, Bronsky EA, Grossman J, et al. Clinical evaluation of triamcinolone acetonide nasal aerosol in children with perennial allergic rhinitis. Ann Allergy 1991; 67: 493–8PubMedGoogle Scholar
  75. 75.
    van As A, Bronsky E, Grossman J, et al. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy 1991; 67: 156–62PubMedGoogle Scholar
  76. 76.
    Kwaselow A, MacLean J, Busse W, et al. A comparison of intranasal and oral flunisolide in the therapy of allergic rhinitis. J Allergy Clin Immunol 1985; 40: 363–7CrossRefGoogle Scholar
  77. 77.
    Lindqvist N, Andersson M, Bende M, et al. The clinical efficacy of budesonide in hay fever treatment is dependent on topical nasal application. Clin Exp Allergy 1989; 19: 71–6PubMedCrossRefGoogle Scholar
  78. 78.
    Hallworth GW, Padfield JM. A comparison of regional deposition in a model nose of a drug discharged from metered aerosol and metered-pump nasal delivery system. J Allergy Clin Immunol 1986; 77: 348–53PubMedCrossRefGoogle Scholar
  79. 79.
    Mygind N, Vesterhauge S. Aerosol distribution in the nose. Rhinology 1978; 16: 79–88PubMedGoogle Scholar
  80. 80.
    Newman SP, Moren F, Clarke SW. Deposition pattern from a nasal pump spray. Rhinology 1987; 25: 77–82PubMedGoogle Scholar
  81. 81.
    Batts AH, Marriott C, Martin GP, et al. The effect of some preservatives used in nasal preparations on mucociliary clearance. J Pharm Pharmacol 1989; 41: 156–9PubMedCrossRefGoogle Scholar
  82. 82.
    Berg ØH, Lie K, Steinvåg SK. The effect of decongestive nosedrops on human respiratory mucosa in vitro. Laryngoscope 1994; 104: 1153–8PubMedCrossRefGoogle Scholar
  83. 83.
    Stafanger G. In vitro effect of beclomethasone dipropionate and flunisolide on mobility of human nasal cilia. Allergy 1987; 42: 507–11PubMedCrossRefGoogle Scholar
  84. 84.
    Orgel HA, Meltzer EO, Kemp JP, et al. Clinical, rhinomanometric, and cytological evaluation of seasonal allergic rhinitis treated with beclomethasone dipropionate as aqueous nasal spray or pressurized aerosol. J Allergy Clin Immunol 1986; 77: 858–64PubMedCrossRefGoogle Scholar
  85. 85.
    Johansen LV, Ilium P, Kristensen S, et al. The effect of budesonide in the treatment of small and medium-sized nasal polyps. Clin Otolaryngol 1993; 18: 524–7CrossRefGoogle Scholar
  86. 86.
    Pedersen B, Larsen BB, Dahl R, et al. Powder administration of pure budesonide for the treatment of seasonal allergic rhinitis. Allergy 1991; 46: 582–7PubMedCrossRefGoogle Scholar
  87. 87.
    Pedersen B, Larsen BB, Dahl R, et al. Budesonide powder administration for the treatment of grass-pollen-induced allergic rhinitis. Allergy 1994; 49: 855–60PubMedCrossRefGoogle Scholar
  88. 88.
    Thorsson L, Newman SP, Weiz A, et al. Nasal distribution of budesonide inhaled via a powder inhaler. Rhinology 1993; 31: 7–10PubMedGoogle Scholar
  89. 89.
    Agertoft L, Wolthers OD, Fuglsang G, et al. Nasal powder administration for seasonal rhinitis in children and adolescents. Pediatr Allergy Immunol 1993; 4: 152–6PubMedCrossRefGoogle Scholar
  90. 90.
    Larsen C, Jørgensen MN, Tommerup B, et al. Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin. Eur J Clin Pharmacol 1987; 33: 155–9PubMedCrossRefGoogle Scholar
  91. 91.
    Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics 1993; 92: 594–9PubMedGoogle Scholar
  92. 92.
    Dahl R. The effect of fluticasone propionate aqueous nasal spray in seasonal rhinitis [abstract]. Allergy 1992; 47Suppl. 12: 346Google Scholar
  93. 93.
    Dolovich J, O’Connor M, Stepner N, et al. Double-blind comparison of intranasal fluticasone propionate, 200µg, once daily with 200µg twice daily in the treatment of patients with severe seasonal allergic rhinitis to ragweed. Ann Allergy 1994; 72: 435–440PubMedGoogle Scholar
  94. 94.
    Malm L, Wihl J-Å. Intranasal beclomethasone dipropionate in vasomotor rhinitis. Acta Allerg (Kbh) 1976; 31: 245–50CrossRefGoogle Scholar
  95. 95.
    Wight RG, Jones AS, Beckingham E, et al. A double-blind comparison of intranasal budesonide 400%g and 800%g in perennial rhinitis. Clin Otolaryngol 1992; 17: 354–8PubMedCrossRefGoogle Scholar
  96. 96.
    Lildholdt T, Rundcrantz H, Lindqvist N. Effect of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of budesonide. Clin Otolaryngol 1995; 20: 26–30PubMedCrossRefGoogle Scholar
  97. 97.
    Munch E, Gomez G, Mygind N, et al. An open comparison of dosage frequency of beclomethasone dipropionate in seasonal allergic rhinitis. Clin Allergy 1981; 11: 303–9PubMedCrossRefGoogle Scholar
  98. 98.
    Nathan RA, Bronsky EA, Fireman P, et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 1991; 67: 332–8PubMedGoogle Scholar
  99. 99.
    Banov CH, Woehler TR, LaForce CF, et al. Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. Ann Allergy 1994; 73: 240–6PubMedGoogle Scholar
  100. 100.
    Bousquet J, Chanal I, Alquié MC, et al. Prevention of pollen rhinitis. Comparison of fluticasone propionate aqueous nasal spray versus disodium cromoglycate nasal spray. Allergy 1993; 48: 327–33PubMedCrossRefGoogle Scholar
  101. 101.
    Beswick KB, Kenyon GS, Cherry JR. A comparative study of beclomethasone dipropionate aqueous nasal spray with terfenadine tablets in season allergic rhinitis. Curr Med Res Opin 1985; 9: 560–7PubMedCrossRefGoogle Scholar
  102. 102.
    Bunnag C, Jareoncharsri P, Wong ECK. A double-blind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis. Allergy 1992; 47: 313–7PubMedCrossRefGoogle Scholar
  103. 103.
    Charpin D, Vervloet D. Treating seasonal rhinitis: antihistamines or intranasal corticosteroids? Eur Respir Rev 1994; 4: 256–9Google Scholar
  104. 104.
    Frølund L. Efficacy of an oral antihistamine, loratadine, as compared with a nasal steroid spray, beclomethasone dipropionate, in seasonal allergic rhinitis. Clin Otolaryngol 1992; 16: 527–31CrossRefGoogle Scholar
  105. 105.
    Harding SM, Heath S. Intranasal steroid aerosol in perennial rhinitis: comparison with an antihistamine compound. Clin Allergy 1976; 6: 369–72PubMedCrossRefGoogle Scholar
  106. 106.
    Juniper EF, Kline PA, Hargreave FE, et al. Comparison of beclomethasone dipropionate aqueous spray, astemizole, and the combination in the prophylactic treatment of ragweed-induced rhinoconjunctivitis. J Allergy Clin Immunol 1989; 83: 627–33PubMedCrossRefGoogle Scholar
  107. 107.
    Munch E, Søborg M, Nørreslet TT, et al. A comparative study of dexchlorpheniramine maleate sustained tablets and budesonide nasal spray in seasonal allergic rhinitis. Allergy 1983; 38: 517–24PubMedCrossRefGoogle Scholar
  108. 108.
    Salomonsson P, Gottberg L, Heilborn H, et al. Efficacy of an oral antihistamine, astemizole, as compared to a nasal steroid spray in hay fever. Allergy 1988; 43: 214–8PubMedCrossRefGoogle Scholar
  109. 109.
    Simpson RJ. Budesonide and terfenadine, separately and in combination, in the treatment of hay fever. Ann Allergy 1994; 73: 497–502PubMedGoogle Scholar
  110. 110.
    Davies RJ, Lund VJ, Harten-Ash VJ. The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. Rhinology 1993; 31: 159–64PubMedGoogle Scholar
  111. 111.
    Dorow P, Aurich R, Petzold U. Efficacy and tolerability of azelastine nasal spray in patients with allergic rhinitis compared to placebo and budesonide. Drug Res 1993; 43: 909–12Google Scholar
  112. 112.
    Gastpar H, Aurich R, Petzold U, et al. Intranasal treatment of perennial allergic rhinitis. Comparison of azelastine nasal spray and budesonide nasal aerosol. Arzneimittelforschung 1993; 43: 475–9PubMedGoogle Scholar
  113. 113.
    Negrini AC, Troise C, Voltolini S, et al. Oral antihistamine/decongestant treatment compared with intranasal corticosteroids in seasonal allergic rhinitis. Clin Exp Allergy 1995; 25: 60–5PubMedCrossRefGoogle Scholar
  114. 114.
    Wood SFG. Oral antihistamine and nasal steroid in hay fever. Clin Allergy 1986; 16: 195–201PubMedCrossRefGoogle Scholar
  115. 115.
    Wihl J-Å, Petersen BN, Petersen LN, et al. Effect of the non-sedative H1-receptor antagonist astemizole in perennial allergic and nonallergic rhinitis. J Allergy Clin Immunol 1985; 75: 720–7PubMedCrossRefGoogle Scholar
  116. 116.
    Benincasa C, Lloyd RS. Evaluation of fluticasone propionate aqueous nasal spray taken alone and in combination with cetirizine in the prophylactic treatment of seasonal allergic rhinitis. Drug Invest 1994; 8: 225–33CrossRefGoogle Scholar
  117. 117.
    Pipkorn U, Rundcrantz H, Lindqvist N. Budesonide — a new nasal steroid. Rhinology 1980; 18: 171–5PubMedGoogle Scholar
  118. 118.
    Siegel SC, Katz R, Rachelefsky GS, et al. Multicenter study of beclomethasone dipropionate in adults with seasonal allergic rhinitis. J Allergy Clin Immunol 1982; 69: 345–53PubMedCrossRefGoogle Scholar
  119. 119.
    Cockcroft DW, MacCormack DW, Newhouse MT, et al. Beclomethasone dipropionate in allergic rhinitis. Can Med Assoc J 1976; 115: 523–6PubMedGoogle Scholar
  120. 120.
    Henriksen J, Wenzel A. Effect of an intranasally administered corticosteroid (budesonide) on nasal obstruction, mouth breathing, and asthma. Am Rev Respir Dis 1984; 130: 1014–8PubMedGoogle Scholar
  121. 121.
    Reed CE, Marcoux JP, Welsh PW. Effects of topical nasal treatment on asthma. J Allergy Clin Immunol 1988; 81: 1042–7PubMedCrossRefGoogle Scholar
  122. 122.
    Aubier M, Levy J, Clerici C, et al. Different effects of nasal and bronchial glucocorticosteroid administration on bronchial hyperresponsiveness in patients with allergic rhinitis. Am Rev Respir Dis 1992; 146: 122–6PubMedGoogle Scholar
  123. 123.
    Corren J, Adinoff AD, Buchmeier AD, et al. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992; 90: 250–6PubMedCrossRefGoogle Scholar
  124. 124.
    Tarlo SM, Cockroft DW, Dolovich J, et al. Beclomethasone dipropionate aerosol in perennial rhinitis. J Allergy Clin Immunol 1977; 59: 232–6PubMedCrossRefGoogle Scholar
  125. 125.
    Hansen I, Mygind N. Local effect of intranasal beclomethasone dipropionate aerosol in perennial rhinitis. Acta Allerg (Kbh) 1974; 29: 281–7CrossRefGoogle Scholar
  126. 126.
    Lindqvist N, Balle V, Karma P, et al. Long term safety and efficacy of budesonide nasal aerosol in perennial rhinitis — a 12 month multicenter study. Allergy 1986; 41: 179–86PubMedCrossRefGoogle Scholar
  127. 127.
    Löfkvist T, Svensson G. Treatment of vasomotor rhinitis with beclomethasone dipropionate. Acta Allerg (Kbh) 1976; 31: 227–38CrossRefGoogle Scholar
  128. 128.
    Pipkorn U, Pukander J, Suonpaa J, et al. Long-term safety of budesonide nasal aerosol — a 5½ year follow up study. Clin Allergy 1988; 18: 253–9PubMedCrossRefGoogle Scholar
  129. 129.
    Feiss G, Welch M, Meltzer E, et al. The predictive value of nasal eosinophilia for therapeutic response to intranasal corticosteroid treatment in perennial allergic rhinitis [abstract]. J Allergy Clin Immunol 1992; 89: 209CrossRefGoogle Scholar
  130. 130.
    Small P, Black M, Frenkiel S. Effect of treatment with beclomethasone dipropionate in subpopulations of perennial rhinitis patients. J Allergy Clin Immunol 1982; 70: 78–82CrossRefGoogle Scholar
  131. 131.
    Whelan CFA. Problems in the examination of nasal smears in allergic rhinitis. J Laryngol Otol 1980; 84: 399–405CrossRefGoogle Scholar
  132. 132.
    Chaplin I, Haynes JT, Spahn I. Are nasal polyps an allergic phenomenon? Ann Allergy 1971; 29: 63–4Google Scholar
  133. 133.
    Delaney JC. Aspirin idiosyncrasy in patients admitted for nasal polypectomy. Clin Otolaryngol 1976; 1: 27–30PubMedCrossRefGoogle Scholar
  134. 134.
    Deuschl H, Drettner B. Nasal polyps treated with beclomethasone nasal aerosol. Rhinology 1977; 15: 17–23PubMedGoogle Scholar
  135. 135.
    Holopainen E, Grahne B, Malmberg H, et al. Budesonide in the treatment of nasal polyposis. Eur J Respir Dis 1982; 63Suppl. 122: 221–8Google Scholar
  136. 136.
    Mygind N, Pedersen CB, Prytz S, et al. Treatment of nasal polyps with intranasal beclomethasone dipropionate aerosol. Clin Allergy 1975; 5: 159–64PubMedCrossRefGoogle Scholar
  137. 137.
    Mygind N, Lildholdt T. Treatment: medical management. In: Settipane GA, Lund VJ, Bernstein JM, et al., editors. Nasal polyps: epidemiology, pathogenesis and treatment. Providence: OceanSide Publications, 1995. In pressGoogle Scholar
  138. 138.
    Drettner B, Ebbesen A, Nilsson M. Prophylactic treatment with flunisolide after polypectomy. Rhinology 1982; 20: 149–58PubMedGoogle Scholar
  139. 139.
    Karlsson G, Rundcrantz H. A randomized trial of intranasal beclomethasone dipropionate after polypectomy. Rhinology 1982; 20: 144–8PubMedGoogle Scholar
  140. 140.
    Farr BM, Gwaltney JM, Hendley JO, et al. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J Infect Dis 1990; 162: 1173–7PubMedCrossRefGoogle Scholar
  141. 141.
    Meltzer EO, Busse WW, Druce HM, et al. Assessment of flunisolide nasal spray versus placebo as an adjunct to antibiotic treatment of sinusitis [abstract]. J Allergy Clin Immunol 1992; 89: 301Google Scholar
  142. 142.
    Sykes DA, Wilson R, Chan KL, et al. Relative importance of antibiotic and improved clearance in topical treatment of chronic mucopurulent rhinosinusitis. Lancet 1986; 2: 359–60PubMedCrossRefGoogle Scholar
  143. 143.
    Boner AL, Sette L. Rhinitis in children: efficacy and safety of a new intranasal corticosteroid. Eur Respir Rev 1994; 20: 271–3Google Scholar
  144. 144.
    Schatz M, Zeiger RS, editors. Asthma and allergy in pregnancy and early infancy. New York: Marcel Dekker, 1993: 1–636Google Scholar
  145. 145.
    Soderberg-Warner ML. Nasal septal perforation associated with topical corticosteroid therapy. J Pediatr 1984; 105: 840–1PubMedCrossRefGoogle Scholar
  146. 146.
    Brown HM, Storey G, Jackson FA. Beclomethasone dipropionate aerosol in treatment of perennial and seasonal rhinitis: a review of five years’ experience. Br J Clin Pharmacol 1977; 4Suppl. 3: 283–6CrossRefGoogle Scholar
  147. 147.
    Sarnstrand B, Jeppsson Å, Malmstrom A, et al. Effect of glucocorticosteroids on hyaluronic acid synthesis in vitro in human fibroblast-like cells from lung and skin. In: Hogg JC, Ellul-Micalef R, Brattsand R, editors. Glucocorticosteroids, inflammation and bronchial hyperreactivity. Amsterdam: Excerpta Medica, 1985: 157–66Google Scholar
  148. 148.
    Frauenfelder FT, Myer SM. Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids. Am J Oph: thalmol 1990; 109: 489–90Google Scholar
  149. 149.
    Simons FE, Persaud MP, Gillespie CA, et al. Absence of posterior cataracts in young patients treated with inhaled glucocorticoids. Lancet 1993; 342: 776–8PubMedCrossRefGoogle Scholar
  150. 150.
    Wolthers OD, Pedersen S. Kneemometry assessment of systemic activity of once daily intranasal dry-powder budesonide in children. Allergy 1994; 49: 96–9PubMedCrossRefGoogle Scholar
  151. 151.
    Knutsson U, Stjärna P, Marcus C, et al. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol. In pressGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Niels Mygind
    • 1
  • Valerie Lund
    • 2
  1. 1.Otopathological Laboratory, Department of Otorhinolaryngology, and Allergy Clinic, Department of Internal MedicineRigshospitaletCopenhagenDenmark
  2. 2.Institute of Laryngology and OtologyUniversity College London Medical SchoolLondonEngland

Personalised recommendations